Capricor Therapeutics
An MSAT Associate 2 supports cGMP manufacturing operations through technical writing, investigation management, and process-focused scientific problem solving in a biotechnology company.
Headquarters
San Diego, California, United States
Company Size
51-200 employees
Founded
2005
Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a San Diego–based biotechnology company developing cell- and exosome-based therapeutics for muscular and other select diseases. Its lead candidate, deramiocel (CAP‑1002), is an allogeneic cell therapy currently in Phase 3 clinical development for Duchenne muscular dystrophy. Capricor is also advancing exosome technology as a next‑generation platform, engineering exosomes to deliver nucleic acids and proteins to treat or prevent a variety of diseases. The company focuses on translating these platforms into novel therapeutic and preventive products.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Capricor Therapeutics.
Capricor Therapeutics didn’t post a salary, so this is our estimate from similar listings.
Duchenne trial drug from Capricor slows key task decline 83%
23 hours ago
Manufacturing Sciences and Technology (MSAT) Process Engineer
Orca Bio
Manufacturing Quality Specialist
Artiva Biotherapeutics
NIGHT SHIFT: Manager, Cell Therapy Manufacturing in Devens, MA
Bristol Myers Squibb
Principal Scientist (PD/MSAT)
Mytos
Director, MSAT
Sana Biotechnology
Executive - MSAT (Upstream)
Intas Pharmaceuticals